The dual PPAR α/γ agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
In 6‐ and 10‐week‐old obesity‐prone (fa/fa) Zucker diabetic fatty (ZDF) rats, effects of prevention and intervention therapies, respectively, were compared between PPAR α/γ agonist, ragaglitazar (RAGA) and separate PPAR γ and α agonists, pioglitazone (PIO) and bezafibrate (BF). In a separate study, lean (+/+) ZDF rats fed highly palatable chow to induce dietary obesity and insulin resistance were treated similarly. To test insulin‐secretory capacity, all animals underwent a hyperglycaemic clamp. Insulin sensitivity was improved equally by RAGA and PIO in fa/fa rats subjected to both prevention and intervention treatments (e.g., prevention HOMA‐IR: −71 and −72%, respectively), as was hyperglycaemia (both −68%). BF had no effect on either parameter in any study. Plasma lipids were markedly reduced (by 48–77%) by RAGA in all studies, equivalent to PIO, but to a greater extent than BF. RAGA improved β‐cell function (HOMA‐β) more than three‐fold with prevention and intervention therapies, whereas PIO showed improvement only in intervention therapy. Consistent with improved insulin sensitivity, glucose infusion rate during the clamp was 60% higher in RAGA‐treated animals subjected to prevention therapy, but there was little additional insulin‐secretory response, suggesting that insulin secretion was already maximal. Thus, RAGA and PIO equally improve metabolic profile in ZDF rats, particularly when administered early in the course of diabetes. They also improve β‐cell function, although this is better demonstrated through indices incorporating fasting insulin and glucose concentrations than through the hyperglycaemic clamp technique in this model. British Journal of Pharmacology (2005) 144, 308–316. doi:10.1038/sj.bjp.0706041
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 1×
“BF may not have had significant effects on most parameters because it is only a moderately weak PPARa agonist compared to fenofibrate in rodents, although potency in humans is approximately equivalent (Willson et al., 2000).”
BackgroundGuerre-Millo, M., Gervois, P., Raspé, E., Madsen, L., Poulain, P., Derudas, B., Herbert, J.-M., Winegar, D. A., Willson, T. M., Fruchart, J.-C., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.22.16638 · Cited by 605
Vettor, R., Pagano, C., Granzotto, M., Englaro, P., Angeli, P., Blum, W. F., Federspil, G., Rohner-Jeanrenaud, F., & Jeanrenaud, B. (1998) · Diabetologia · doi:10.1007/s001250051077 · Cited by 20 · cited 1×
“A priming infusion of 20% D-glucose in water (w v 1) was then begun at a rate of 100mg kgmin 1, and was gradually reduced to 70, 57, 46 and 35mgkgmin 1 every 2min for the first 11min of infusion, based on the method of Vettor et al. (1998).”
Method
Cited by
International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors
Michalik, L., Auwerx, J., Berger, J. P., Chatterjee, V. K., Glass, C. K., Gonzalez, F. J., Grimaldi, P. A., Kadowaki, T., Lazar, M. A., O’Rahilly, S., et al. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.5 · Cited by 1,000
Peroxisome proliferator-activated receptor-γ ligands for the treatment of breast cancer
Fenner, M. H., & Elstner, E. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.557 · Cited by 88
van Poelje, P. D., Potter, S. C., Chandramouli, V. C., Landau, B. R., Dang, Q., & Erion, M. D. (2006) · Diabetes · doi:10.2337/db05-1443 · Cited by 87
Zhang, H.-M., Chen, S.-W., Zhang, L.-S., & Feng, X.-F. (2008) · Natural Product Research · doi:10.1080/14786410701869598 · Cited by 23
Metadata
- Authors
- Pickavance, L. C., Brand, C. L., Wassermann, K., & Wilding, J. P. H.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2005-02
- Volume
- 144
- Issue
- 3
- Pages
- 308-316
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1974569331
- Cited by
- 71
- References
- 5
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.